CAPR Capricor Therapeutics, Inc. Stock Quote

CAPR [NASD]

Index	-	P/E	-	EPS (ttm)	-0.94	Insider Own	2.27%	Shs Outstand	20.41M	Perf Week	-8.66%
Market Cap	92.07M	Forward P/E	-	EPS next Y	-1.06	Insider Trans	0.00%	Shs Float	19.93M	Perf Month	-24.20%
Income	-13.70M	PEG	-	EPS next Q	-	Inst Own	6.50%	Short Float	2.17%	Perf Quarter	-17.15%
Sales	0.30M	P/S	306.90	EPS this Y	57.40%	Inst Trans	19.74%	Short Ratio	0.63	Perf Half Y	-17.32%
Book/sh	1.38	P/B	2.91	EPS next Y	-6.00%	ROA	-44.70%	Target Price	-	Perf Year	172.79%
Cash/sh	1.42	P/C	2.82	EPS next 5Y	-	ROE	-54.70%	52W Range	1.40 - 12.32	Perf YTD	16.91%
Dividend	-	P/FCF	-	EPS past 5Y	35.90%	ROI	-43.10%	52W High	-67.45%	Beta	6.52
Dividend %	-	Quick Ratio	11.30	Sales past 5Y	-43.80%	Gross Margin	-	52W Low	186.43%	ATR	0.30
Employees	26	Current Ratio	11.30	Sales Q/Q	-50.00%	Oper. Margin	-	RSI (14)	29.66	Volatility	6.42% 6.38%
Optionable	Yes	Debt/Eq	0.13	EPS Q/Q	39.50%	Profit Margin	-	Rel Volume	0.46	Prev Close	4.02
Shortable	Yes	LT Debt/Eq	0.12	Earnings	Mar 11 AMC	Payout	-	Avg Volume	682.77K	Price	4.01
Recom	2.00	SMA20	-14.39%	SMA50	-29.44%	SMA200	-23.62%	Volume	317,136	Change	-0.25%

Dec-26-18

Downgrade

Maxim Group

Buy → Hold

Jan-26-18

Reiterated

H.C. Wainwright

Buy

$6.50 → $8.60

Sep-15-17

Reiterated

H.C. Wainwright

Buy

$2.15 → $6.50

Feb-13-17

Resumed

Rodman & Renshaw

Buy

$14

Jul-06-16

Resumed

H.C. Wainwright

Buy

$13

Jun-15-16

Initiated

ROTH Capital

Buy

Mar-13-21 01:28AM	Breakeven On The Horizon For Capricor Therapeutics, Inc. (NASDAQ:CAPR) Simply Wall St.
Mar-11-21 04:01PM	Capricor Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update GlobeNewswire
02:30PM	Capricor Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Mar-09-21 09:15AM	Capricor Therapeutics Announces New Advances in Exosome-Mediated mRNA Delivery Platform GlobeNewswire +5.63%
Mar-04-21 09:00AM	Capricor Therapeutics to Present Fourth Quarter and Full Year 2020 Financial Results and Recent Corporate Update on March 11 GlobeNewswire -11.54%
Feb-01-21 09:15AM	Capricor Therapeutics Announces Development of Serology Test to Confirm Activity of SARS-CoV-2 Vaccines GlobeNewswire
Jan-19-21 09:15AM	Capricor Therapeutics Announces Publication Demonstrating Methods for Enhanced Potency of Cardiosphere-Derived Exosomes GlobeNewswire +9.02%
Jan-12-21 09:05AM	Capricor Collaborates with Lonza for the Development of CAP-1002, its Cell Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy and Other Indications GlobeNewswire +11.85%
Dec-29-20 09:15AM	Capricor Therapeutics Announces DSMB Recommendation to Continue Phase II INSPIRE Trial for Severe COVID-19 Patients GlobeNewswire -5.45%
Nov-24-20 07:30AM	Capricor Therapeutics Commences Dosing Patients in Phase 2 Trial of CAP-1002 in Patients with Severe COVID-19 GlobeNewswire
Nov-12-20 04:01PM	Capricor Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire
02:30PM	Capricor Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Nov-09-20 09:15AM	Capricor Therapeutics Announces Positive Preclinical Data for Multivalent Exosome-mRNA Vaccine For COVID-19 GlobeNewswire
Nov-05-20 09:00AM	Capricor Therapeutics to Present Third Quarter 2020 Financial Results and Recent Corporate Update on November 12 GlobeNewswire
Sep-23-20 09:25AM	Capricor Therapeutics to Present Results from the HOPE-2 Trial with CAP-1002 in Duchenne Muscular Dystrophy at the International World Muscle Society Virtual Congress 2020 GlobeNewswire
Sep-10-20 09:15AM	Capricor Therapeutics to Present at H.C. Wainwright 22nd Annual Global Investment Conference GlobeNewswire +5.41%
Sep-01-20 04:34PM	LD Micro: 360 Companies--Set to Present this Week. ACCESSWIRE -7.63%
Aug-31-20 09:00AM	Capricor Therapeutics to Present at The LD 500 Virtual Conference ACCESSWIRE +14.64%
Aug-25-20 11:34AM	Why Capricor Therapeutics Is Trading Higher Today Benzinga
09:15AM	Capricor Therapeutics Announces U.S. FDA Acceptance of its IND Application for a Phase 2 Clinical Trial of CAP-1002 in Patients with COVID-19 GlobeNewswire
Aug-06-20 04:01PM	Capricor Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire
Jul-30-20 09:15AM	Capricor Therapeutics to Present Second Quarter 2020 Financial Results and Recent Corporate Update on August 6 GlobeNewswire -18.66%
Jul-28-20 12:33PM	Capricor Therapeutics (CAPR) May Report Negative Earnings: Know the Trend Ahead of Q2 Release Zacks
Jul-23-20 07:28AM	Capricor Therapeutics (NASDAQ:CAPR) Is In A Good Position To Deliver On Growth Plans Simply Wall St.
Jun-04-20 09:15AM	Capricor to Participate in BIO Digital International Convention GlobeNewswire
May-29-20 01:08PM	Here is What Hedge Funds Think About Capricor Therapeutics, Inc. (CAPR) Insider Monkey +5.94%
May-26-20 09:25AM	Capricor to Participate in Maxim Group's COVID-19 Virtual Conference Series on May 27, 2020 GlobeNewswire
May-14-20 05:35PM	Capricor Therapeutics (CAPR) Reports Q1 Loss, Lags Revenue Estimates Zacks
04:01PM	Capricor Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire
May-13-20 04:30PM	Capricor Therapeutics to Present First Quarter 2020 Financial Results and Recent Corporate Update on May 14 GlobeNewswire -15.70%
07:00AM	Capricor Announces Positive Top-Line Final Results from HOPE-2 Study in Patients with Duchenne Muscular Dystrophy Treated with Lead Candidate CAP-1002 GlobeNewswire
May-06-20 06:44PM	Capricor (CAPR) Shares Could Hit $10, Says Analyst SmarterAnalyst
Apr-30-20 12:23AM	Capricor Therapeutics Shares Soar 250% On Successful COVID-19 Treatment News Benzinga -17.65%
Apr-29-20 09:15AM	New Capricor Data Reports 100 Percent Survival in Critical COVID-19 Patients Treated with CAP-1002 GlobeNewswire +252.70%
Apr-24-20 07:31AM	Did You Manage To Avoid Capricor Therapeutics' (NASDAQ:CAPR) 97% Share Price Wipe Out? Simply Wall St. +25.13%
Apr-13-20 09:00AM	Capricor Therapeutics to Host Key Opinion Leader Call on Cardiac Complications of Duchenne Muscular Dystrophy GlobeNewswire
Apr-06-20 04:02PM	This Penny Stock Joins the Fight Against Coronavirus; Analyst Sees Triple-Digit Upside TipRanks +10.00%
Apr-03-20 08:00AM	Capricor Initiates Compassionate Use Program for Severe COVID-19 Patients using CAP-1002, its Novel Cell Therapy GlobeNewswire
Mar-24-20 08:00AM	Capricor Therapeutics to Host a Key Opinion Leader Call On Why Exosomes are Uniquely Suited for Vaccine Development GlobeNewswire +51.72%
Mar-19-20 08:30AM	4 MedTech Stocks to Scoop Up Amid the Coronavirus Crisis Zacks +5.36%
Mar-18-20 04:01PM	Capricor Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update GlobeNewswire
02:30PM	Capricor Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Mar-17-20 08:00AM	Capricor Therapeutics Announces Strategic Plan for Exosome Platform Technology Products Expansion GlobeNewswire +15.84%
Mar-11-20 04:30PM	Capricor Therapeutics to Present Fourth Quarter and Full Year 2019 Financial Results and Recent Corporate Update on March 18 GlobeNewswire +6.91%
Mar-10-20 07:01AM	Does Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO Pay Reflect Performance? Simply Wall St.
Feb-13-20 11:30AM	Is Capricor Therapeutics (CAPR) Outperforming Other Medical Stocks This Year? Zacks
Feb-07-20 04:12PM	Casper Sleep shares slide 18% on second day of trading, falling below $12 IPO issue price MarketWatch
Feb-03-20 07:39AM	Top Ranked Momentum Stocks to Buy for February 3rd Zacks
Jan-28-20 07:01AM	Top Ranked Momentum Stocks to Buy for January 28th Zacks
Dec-19-19 01:14PM	Capricor Therapeutics Announces Closing of $5.1 Million Offering Priced At-the-Market GlobeNewswire -5.31%
Dec-17-19 01:52PM	Capricor Therapeutics Announces Pricing of $5.1 Million Offering Priced At-the-Market GlobeNewswire -5.45%
Dec-11-19 05:29AM	We're A Little Worried About Capricor Therapeutics's (NASDAQ:CAPR) Cash Burn Rate Simply Wall St.
Nov-07-19 05:15PM	Capricor Therapeutics (CAPR) Reports Q3 Loss, Lags Revenue Estimates Zacks
04:00PM	Capricor Therapeutics Reports Third Quarter 2019 Financial Results and Provides Recent Corporate Update GlobeNewswire
Nov-01-19 09:00AM	Capricor Therapeutics to Present Third Quarter 2019 Financial Results and Recent Corporate Update on November 7 GlobeNewswire
Oct-27-19 09:16AM	How Capricor Therapeutics, Inc. (NASDAQ:CAPR) Can Impact Your Portfolio Volatility Simply Wall St.
Oct-21-19 09:25AM	Capricor Therapeutics to Host Key Opinion Leader Call on the Role of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy (DMD) GlobeNewswire
Oct-14-19 09:35AM	CHF Solutions System to be Used in JAHVH Study After Final Nod Zacks
Oct-07-19 12:27PM	A Look At Benzinga Pro's Most-Searched Tickers For October 7, 2019 Benzinga -10.42%
06:30AM	Capricor Presents Additional Positive Data from Ongoing HOPE-2 Study of CAP-1002 in Duchenne Muscular Dystrophy at World Muscle Society: Data Demonstrates Improved PUL 2.0 Performance at 6 Months GlobeNewswire
Oct-04-19 10:09AM	Zynex (ZYXI) Scales 52-Week High: What's Driving the Stock? Zacks
Oct-02-19 09:15AM	Capricor to Present Interim Results from the HOPE-2 Trial in a Late Breaking Session of the World Muscle Society and Company to Host Conference Call Monday, October 7 at 5:30 AM PT / 8:30 AM ET GlobeNewswire
Oct-01-19 09:14AM	Abbott (ABT) Gets FDA Nod for Spinal Cord Stimulation System Zacks
Sep-26-19 11:24AM	Align Gains on Innovation Despite Poor Case Shipment in China Zacks
09:47AM	Natera (NTRA) Scales 52-Week High: What's Driving the Stock? Zacks
Sep-25-19 08:44AM	Illumina (ILMN) Inks Deal to Develop Distributable Test Kits Zacks
Sep-24-19 11:25AM	FDA Nods to Medtronic's (MDT) New Age Evolut PRO+ TAVR Zacks
09:20AM	Insulet Receives FDA Approval for ACE Pump Implementation Zacks
07:42AM	Capricor Therapeutics shares climb 3.6% on news FDA to meet to discuss DMD treatment MarketWatch
07:30AM	Capricor Therapeutics to Meet with FDA to Discuss CAP-1002 to Treat Duchenne Muscular Dystrophy GlobeNewswire
Sep-23-19 09:44AM	Bruker (BRKR) Enters Into Alliance With Murdoch University Zacks
Sep-21-19 08:20AM	Did You Manage To Avoid Capricor Therapeutics's (NASDAQ:CAPR) Devastating 92% Share Price Drop? Simply Wall St.
Sep-20-19 09:12AM	Neogen Forms Partnership With IGS to Enhance Beef Profile Zacks +8.42%
Sep-19-19 08:41AM	Medtronic Receives European Nod for Glucose Monitoring System Zacks
Sep-17-19 12:29PM	A Look At Benzinga Pro's Most-Searched Tickers For September 17, 2019 Benzinga +13.60%
08:38AM	Abbott Partners With Sanofi to Upgrade Diabetes Management Zacks
07:00AM	Capricor Therapeutics to Present Results from the HOPE-2 Trial of CAP-1002 in Duchenne Muscular Dystrophy in a Late Breaking Session of the World Muscle Society GlobeNewswire
Sep-11-19 09:04AM	Baxter's (BAX) Cheetah Acquisition to Aid Patient Monitoring Zacks
Sep-06-19 07:30AM	Capricor Therapeutics to Present at Upcoming Conferences GlobeNewswire +5.12%
Aug-23-19 08:37AM	Neogen Gets AOAC Validation for NeoSeek to Ensure Food Safety Zacks
Aug-22-19 07:31AM	NuVasive's New TLIF Implant Broadens Spine Surgery Option Zacks
Aug-20-19 09:03AM	Boston Scientific's (BSX) Vercise Gevia DBS Gets FDA Nod Zacks -8.03%
Aug-16-19 10:24AM	Here's What We Think About Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO Pay Simply Wall St.
Aug-06-19 06:05PM	Capricor Therapeutics (CAPR) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:00PM	Capricor Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
Aug-01-19 10:32AM	Will Capricor Therapeutics (CAPR) Report Negative Q2 Earnings? What You Should Know Zacks -9.55%
Jul-30-19 08:00AM	Capricor Therapeutics to Present Second Quarter 2019 Financial Results and Recent Corporate Update on August 6 GlobeNewswire
Jul-25-19 07:00AM	Capricor Therapeutics Announces Positive DSMB Safety and Futility Review and Continuation of its HOPE-2 Study in Duchenne Muscular Dystrophy GlobeNewswire +5.46%
Jul-17-19 07:00AM	Capricor Therapeutics and Parents Project Muscular Dystrophy to Host Webinar to Discuss Interim Analysis of the HOPE-2 Clinical Trial to Treat Patients with Duchenne Muscular Dystrophy GlobeNewswire -5.00%
Jul-16-19 12:44PM	A Look At Benzinga Pro's Most-Searched Tickers For July 16, 2019 Benzinga
Jul-15-19 02:59PM	Capricor Therapeutics News: Why CAPR Stock Is Skyrocketing Today InvestorPlace +93.48%
08:45AM	Capicor Therapeutics' stock rockets on heavy volume after positive MD trial results MarketWatch
06:00AM	Capricor Therapeutics Announces Positive Results from its Interim Analysis in the HOPE-2 Trial to Treat Patients with Duchenne Muscular Dystrophy GlobeNewswire
Jul-02-19 02:23PM	What Kind Of Shareholders Own Capricor Therapeutics, Inc. (NASDAQ:CAPR)? Simply Wall St.
May-13-19 05:15PM	Capricor Therapeutics (CAPR) Reports Q1 Loss, Lags Revenue Estimates Zacks
04:06PM	Capricor: 1Q Earnings Snapshot Associated Press
04:00PM	Capricor Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
02:30PM	Capricor Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
May-06-19 04:00PM	Capricor Therapeutics to Present First Quarter 2019 Financial Results and Recent Corporate Update on May 13 GlobeNewswire
Apr-05-19 10:52AM	Will Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) Earnings Grow In The Years Ahead? Simply Wall St.

Capricor Therapeutics, Inc., a biotechnology company, focuses on the development of transformative cell- and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases. The company's lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase II clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with COVID-19; and completed various trials investigating the use of CAP-1002 for the treatment of cardiac conditions, including heart failure and post myocardial infarction with cardiac dysfunction. It is also developing CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in preclinical stage for the potential prevention of COVID-19. Capricor collaborates with Lonza Houston, Inc. for the development of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in Beverly Hills, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Manzo Louis	Director	Sep 24	Option Exercise	3.70	8,299	30,706	44,603	Sep 28 08:30 AM
Marban Linda	CHIEF EXECUTIVE OFFICER	Jul 27	Option Exercise	3.70	41,497	153,539	62,367	Jul 29 06:39 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience